NR4A1 and prostate carcinoma: In particular, p300 is reported to be a key mediator of oncogenic hormone receptor signaling in hormone receptor positive breast and prostate cancers [36] whereby it promotes the expression of estrogen or androgen receptors, respectively [37, 38].